share_log

Novartis AG | 6-K: Novartis Investigational Iptacopan Phase Iii Study Demonstrates Clinically Meaningful and Statistically Significant Proteinuria Reduction in Patients with C3 Glomerulopathy (C3g)

Dec 11, 2023 06:05
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more